Home / Press Releases / CSRA’s DynPort Vaccine Company Gets Orphan Drug Designation on Plague Vaccine

CSRA’s DynPort Vaccine Company Gets Orphan Drug Designation on Plague Vaccine

TYSONS CORNER, VA, March 10, 2017 — A subsidiary of CSRA (NYSE: CSRA) has secured orphan drug status from the Food and Drug Administration on a plague vaccine it is developing as a potential pre-exposure prophlaxis treatment against Yersinia pestis infection, ExecutiveBiz reported Thursday.

The company said Wednesday the designation enables DynPort Vaccine Company to receive incentives in its work to develop the recombinant rF1V vaccine as part of the Defense Department‘s medical countermeasure efforts against bioterrorism.

About Executive Mosaic: Founded in 2002, Executive Mosaic is a leadership organization and media company. Executive Mosaic offers highly coveted executive events, breaking business news on the Government Contracting industry, and delivers robust and reliable content through seven influential websites and four consequential E-newswires. Headquarters are located in Tysons Corner, VA. www.executivemosaic.com

Contact:
David Smith
(703) 226-7002
david.smith@executivemosaic.com

Check Also

DoD Inspector General to Review JEDI Cloud Contract

The Department of Defense’s inspector general has formed a team of auditors to assess the potential 10-year, $10B Joint Enterprise Defense Infrastructure cloud computing contract, the Washington Post reported Tuesday.

Capgemini Government Solutions to Provide CoE IT Support Under GSA BPA; Doug Lane Quoted

TYSONS CORNER, VA, August 13, 2019 — Capgemini’s government solutions business has received a spot under a three-year blanket purchase agreement from the General Services Administration to be a vendor of information technology products and services to government agencies in support of IT modernization efforts, ExecutiveGov reported July 31.